This might represent a case of BPDCN arising from clonal hematopoiesis, a concept that has previously been demonstrated for BPDCN [19] and supports the interpretation that KRAS acted as a disease-driving alteration in this case. The gene discussed is KRAS; the disease is CD4+/CD56+ hematodermic neoplasm.